Patents by Inventor Mariko FONSECA

Mariko FONSECA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD OF PURIFYING ALBUMIN-FUSION PROTEINS
    Publication number: 20230340074
    Abstract: The present invention relates to a method of purifying albumin-fusion proteins to reduce the level of oxidation of susceptible amino acid residues. The method comprises an affinity matrix chromatography step and an anion exchange chromatography step. The purified albumin-fusion proteins have low levels of oxidation and retain their enhanced half-life in vivo and its bioactivity. In some embodiments, the albumin-fusion protein comprises a scaffold, such as human Tenascin C scaffold. Compositions comprising the albumin-fusion protein are further disclosed.
    Type: Application
    Filed: January 6, 2023
    Publication date: October 26, 2023
    Inventors: Timothy PABST, Mariko FONSECA, Christopher THOMPSON, Alan HUNTER, Xiangyang WANG, Liu TIE, Yiming LI
  • Method of purifying albumin-fusion proteins
    Patent number: 11548933
    Abstract: The present invention relates to a method of purifying albumin-fusion proteins to reduce the level of oxidation of susceptible amino acid residues. The method comprises an affinity matrix chromatography step and an anion exchange chromatography step. The purified albumin-fusion proteins have low levels of oxidation and retain their enhanced half-life in vivo and its bioactivity. In some embodiments, the albumin-fusion protein comprises a scaffold, such as human Tenascin C scaffold. Compositions comprising the albumin-fusion protein are further disclosed.
    Type: Grant
    Filed: June 15, 2020
    Date of Patent: January 10, 2023
    Assignee: Medlmmune, LLC
    Inventors: Timothy Pabst, Mariko Fonseca, Christopher Thompson, Alan Hunter, Xiangyang Wang, Liu Tie, Yiming Li
  • METHOD OF PURIFYING ALBUMIN-FUSION PROTEINS
    Publication number: 20200407423
    Abstract: The present invention relates to a method of purifying albumin-fusion proteins to reduce the level of oxidation of susceptible amino acid residues. The method comprises an affinity matrix chromatography step and an anion exchange chromatography step. The purified albumin-fusion proteins have low levels of oxidation and retain their enhanced half-life in vivo and its bioactivity. In some embodiments, the albumin-fusion protein comprises a scaffold, such as human Tenascin C scaffold. Compositions comprising the albumin-fusion protein are further disclosed.
    Type: Application
    Filed: June 15, 2020
    Publication date: December 31, 2020
    Inventors: Timothy PABST, Mariko FONSECA, Christopher THOMPSON, Alan HUNTER, Xiangyang WANG, Liu TIE, Yiming LI
  • Method of purifying albumin-fusion proteins
    Patent number: 10683340
    Abstract: The present invention relates to a method of purifying albumin-fusion proteins to reduce the level of oxidation of susceptible amino acid residues. The method comprises an affinity matrix chromatography step and an anion exchange chromatography step. The purified albumin-fusion proteins have low levels of oxidation and retain their enhanced half-life in vivo and its bioactivity. In some embodiments, the albumin-fusion protein comprises a scaffold, such as human Tenascin C scaffold. Compositions comprising the albumin-fusion protein are further disclosed.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: June 16, 2020
    Assignee: MedImmune, LLC
    Inventors: Timothy Pabst, Mariko Fonseca, Christopher Thompson, Alan Hunter, Xiangyang Wang, Liu Tie, Yiming Li
  • METHOD OF PURIFYING ALBUMIN-FUSION PROTEINS
    Publication number: 20180105575
    Abstract: The present invention relates to a method of purifying albumin-fusion proteins to reduce the level of oxidation of susceptible amino acid residues. The method comprises an affinity matrix chromatography step and an anion exchange chromatography step. The purified albumin-fusion proteins have low levels of oxidation and retain their enhanced half-life in vivo and its bioactivity. In some embodiments, the albumin-fusion protein comprises a scaffold, such as human Tenascin C scaffold. Compositions comprising the albumin-fusion protein are further disclosed.
    Type: Application
    Filed: March 11, 2016
    Publication date: April 19, 2018
    Inventors: Timothy PABST, Mariko FONSECA, Christopher THOMPSON, Alan HUNTER, Xiangyang WANG, Liu TIE, Yiming LI